Lifecare ASA

LIFE: Lifecare ASA Q3 2026 results

Källa: MFN
Positiv

Sammanfattning

Lifecare ASA publicerar sin Q3 2026 rapport med positiva nyheter om framsteg i tillverkningen av CGM-implantat och en förvärvad infrastruktur. Bolaget har också lyckats minska sina rörelsekostnader markant.

Analys

Lifecare ASA visar betydande operativa framsteg i Q3 2026, med framgångsrik tillverkning av funktionella CGM-implantat och en minskning av rörelseförlusten till 12,2 MSEK från 65,9 MSEK föregående år. Förvärvet av Ocean TuniCell stärker bolagets infrastruktur och expertis. Kassaflödet ger runway in i Q2 2027, vilket är positivt givet den tidigare omstruktureringen.

VD-ord

optimistisk · PDF

Lifecare har framgångsrikt tillverkat funktionella CGM-implantat internt, vilket är ett steg mot industrialisering. Förvärvet av Ocean TuniCell stärker den industriella basen och breddar teknikplattformen.

Utsikter: Fokus ligger på att etablera tillverkning, verifiering och regulatorisk grund för en klinisk undersökning för CE-märkning.

Nyckeltal

Rörelseförlust Q3 2026
NOK 12.2 million
Rörelseförlust Q3 2025
NOK 65.9 million
Kassa vid kvartalets slut
NOK 30.3 million

Insikter

  • • Förvärvet av Ocean TuniCell verkar vara strategiskt för att snabba på produktutvecklingen.
  • • Fokus ligger fortsatt på CE-märkning och klinisk utveckling.
  • • Tekniken har potential att expandera bortom glukosmonitorering.
Fundamental påverkan
Positiv

Bolaget visar framsteg i sin produktutveckling och kostnadskontroll, vilket stärker dess finansiella ställning och framtida potential.

Omfattning: 6/10Materiell påverkan
0 · Ingen påverkan10 · Avgörande påverkan

Poängen visar omfattning, inte förväntad kursrörelse.

Bergen, Norway, 12 November 2026: Today, Lifecare ASA (LIFE), a medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes its Q3 2026 financial report and operational update.

Bergen, Norway, 12 November 2026: Today, Lifecare ASA (LIFE), a medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes its Q3 2026 financial report and operational update.

Highlights:

  • First functional CGM implants successfully manufactured at Lifecare’s facilities in Bergen
  • Subsequent production batches demonstrate encouraging progress towards repeatable manufacturing processes
  • Acquisition of Ocean TuniCell provides established laboratory and cleanroom infrastructure, specialised equipment and biological and laboratory expertise in Bergen
  • Scientific development expands the opportunity for Lifecare’s osmotic sensing technology beyond glucose, while CGM remains the primary operational priority
  • The operational restructuring initiated in Q1 2026 has materially reduced the Company’s cost base. The operating loss for Q3 2026 was NOK 12.2 million, compared with NOK 65.9 million in Q3 2025, reflecting a more focused operating model
  • Cash position of NOK 30.3 million at quarter end, with the current operating plan expected to provide runway into Q2 2027

During the third quarter, Lifecare achieved a significant operational milestone by successfully manufacturing its first functional CGM implants at the Company’s facilities in Bergen. Subsequent manufacturing runs and batches in October have demonstrated encouraging progress towards establishing repeatable production processes.

“This gives us a substantially stronger foundation for systematic product testing, process optimisation and the generation of the evidence required for clinical and regulatory development,” says Lifecare CEO Joacim Holter.

The acquisition of Ocean TuniCell provides a faster and more capital-efficient route towards developing Lifecare’s controlled manufacturing capabilities than establishing equivalent infrastructure independently. Ocean TuniCell also adds a proprietary nanofibrillar cellulose technology platform with independent scientific and commercial opportunities.

“The acquisition of Ocean TuniCell had an immediate positive effect on our operations. Progressing Lifecare’s manufacturing and engineering, combined with the biological expertise, testing and infrastructure capabilities of Ocean TuniCell, significantly strengthen our execution capacity in Bergen,” Holter says.

Lifecare’s immediate priority remains to establish reproducible, controlled manufacturing and complete the verification and documentation required for the planned pivotal CE-mark clinical investigation.

Results presentationCEO Joacim Holter and CFO Petter Nielsen will present the Q3 results on webcast today at 10:00 CET. To access the webcast join the meeting here.

A recording of the webcast will be available on our website after the event.

About usLifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

ContactsFor further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-12 07:00 CET.

AttachmentsLifecare Q3 2026 ReportLifecare Q3 2026 Presentation

Öppna PDF